DGAP-News: Aladdin Healthcare Technologies SE signs MOU with partner in India to validate and distribute COVID-19 diagnosis prototype

Aladdin Healthcare Technologies SE signs MOU with partner in India to validate and distribute COVID-19 diagnosis prototype

BERLIN/LONDON, 16 March 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of A.I healthcare diagnostics and drug discovery applications for age-related diseases, has successfully signed a memorandum of understanding (MOU) with the OurHealthMate India (OHM) to validate and subsequently distribute its COVID-19 diagnosis prototype through their industry network.

- OHM is recognised by clinicians of the Indian Medical Council and have access to their databases, ensuring that they only work with and provide appointments with accredited healthcare providers.

- It is India's largest healthcare marketplace with 40,000 doctors on their system and more than 350,000 medical services available. They are integrated with over 2,000 healthcare centers in India, including the majority of the large hospital chains in India.

- The platform has access to millions of patients and currently hosts more than 1,500,000 medical records on its platform.

Access to quality data is vital for accuracy of any COVID-19 diagnosis tool. This is the problem facing any company that is attempting to develop a rapid and accurate product. As a result of this partnership, Aladdin will have access to Indian data as part of a global resource of high-quality data, putting the company at a significant advantage to competitors.

The capability of the prototype, once validated, will be expanded so that it can recognise and diagnose other pulmonary diseases in real time. Meaning the commercial longevity of the product will reach far beyond the COVID-19.

"We intend to push this product out to millions of patients within India over the next 2 years post validation for both COVID-19 and other pulmonary diseases diagnosis. This should culminate in Aladdin becoming an early leader in A.I. imaging services for complex medical conditions in India," said Wade Menpes-Smith, CEO von Aladdin Healthcare Technologies SE.

A public offering of shares in the company is open and runs from 9 to 30 March 2020.

Further information is available at:
https://aladdinid.com/de/investorrelations/

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets aged related disease including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by the award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, the AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone +49 89 1250 90330
Email: sh@crossalliance.de
www.crossalliance.de